Why it matters: GLP-1 use surged in 2025 and will grow this year as the drugs expand beyond diabetes and weight loss into cardiovascular, kidney and liver disease, sleep apnea, and other indications in development
Knockdown of GLP-1Rs in the LS, rather than in the PVN, attenuates the food intake and body weightreducing effects of liraglutide
Hence, the more beneficial work in microflora disorders is promising in the treatment of autoimmune diseases, as well as intestinal microbiota [74]
Choosing the Right Regenerative Medicine Clinic When youre exploring peptide therapy, the clinic you choose makes all the difference
Growth in advanced and complex molecules (biologics, [monoclonal antibodies] mAbs, novel modalities) is reshaping injectable development, Campbell said